Fulgent Genetics (NASDAQ: FLGT)
Fulgent Genetics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Fulgent Genetics Company Info
Fulgent Genetics is a technology company that provides comprehensive diagnostic genetic testing using its proprietary platform, which integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes.
News & Analysis
Investing in Genetic Testing Stocks
Fulgent Genetics Revenue Tops Estimates
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.
Investing in Genomics Stocks
Fulgent Genetics: EPS Exceeds Forecast
The company is successfully pivoting away from COVID-19 services.
Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue
The genetic testing company's core business is growing, but it's still generating red ink.
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
Fulgent is moving past its pandemic-era business, and that's a good thing.
1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings
Strong core business growth was overshadowed in Q3 by an acquisition.
Why I Bought More of This Under-the-Radar Stock
This healthcare business has tailwinds behind it.
Valuation
Earnings Transcripts
Fulgent Genetics, Inc. (FLGT) Q2 2022 Earnings Call Transcript
FLGT earnings call for the period ending June 30, 2022.
Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Call Transcript
FLGT earnings call for the period ending March 31, 2022.
Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Call Transcript
FLGT earnings call for the period ending December 31, 2021.
Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earnings Call Transcript
FLGT earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.